BioRestorative Therapies Stock (NASDAQ:BRTX)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.55

52W Range

$1.03 - $3.67

50D Avg

$1.54

200D Avg

$1.53

Market Cap

$10.52M

Avg Vol (3M)

$48.57K

Beta

62.82

Div Yield

-

BRTX Company Profile


BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

11

IPO Date

Dec 05, 2012

Website

BRTX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 24Jun 24
Royalty$2.90K$19.80K
Product$230.70K$69.30K

Fiscal year ends in Dec 23 | Currency in USD

BRTX Financial Summary


Dec 23Dec 22Dec 21
Revenue$145.80K$119.80K$46.00K
Operating Income$-15.22M$-18.97M$-26.31M
Net Income$-14.42M$-18.02M$-29.94M
EBITDA$-15.22M$-18.99M$-42.40M
Basic EPS$-3.42$-4.98$-25.21
Diluted EPS$-3.42$-4.98$-25.21

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 13, 24 | 7:53 PM
Q2 24Aug 13, 24 | 11:26 PM
Q1 24May 14, 24 | 7:08 PM

Peer Comparison


TickerCompany
SLNOSoleno Therapeutics, Inc.
CINGCingulate Inc.
MNPRMonopar Therapeutics Inc.
PULMPulmatrix, Inc.
SABSSAB Biotherapeutics, Inc.
XTLBXTL Biopharmaceuticals Ltd.
BPTHBio-Path Holdings, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
CAPRCapricor Therapeutics, Inc.
CADLCandel Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
AKTXAkari Therapeutics, Plc
ACHVAchieve Life Sciences, Inc.